.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
IHH Healthcare has recently identified India as a high-priority growth market. Consequently, the group aims to accelerate the Fortis Healthcare expansion to become a top private healthcare player. Group CEO Prem Kumar Nair announced plans to increase IHH’s stake in Fortis to 50% over the medium term. This strategic move follows the resolution of the mandatory tender offer. Moreover, the group believes this investment will strengthen its clinical footprint across Asia.
The group plans to increase its bed capacity to 10,000 in India by 2030. Furthermore, IHH has committed a capital expenditure of ₹2,500 crore for the next three years. This investment will primarily fund brownfield projects at existing facilities. For instance, expansion will target clusters in Punjab, Jalandhar, and Bengaluru. Additionally, the group will fully integrate Gleneagles into the Fortis network. Currently, the network spans 36 hospitals across the country.
Nair emphasized that growth must not compromise clinical quality. He believes that high-intensive-care beds are more valuable than a high volume of low-quality beds. Currently, Fortis operates with strong profitability levels. The group reports EBITDA margins between 23% and 24%. Therefore, the increased investment is expected to be earnings-per-share accretive. Meanwhile, IHH is also repositioning its diagnostics arm, Agilus, to focus on high-end genomics.
Q1: What is the target stake for IHH in Fortis?
IHH Healthcare aims to increase its shareholding in Fortis Healthcare to 50% over the medium term to drive long-term value.
Q2: How many beds does IHH plan to have in India?
The group targets a total of 10,000 beds in India by 2030 through strategic brownfield expansion and full network integration.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
IHH Healthcare plans to hike its stake in Fortis to 50% and expand capacity to 10,000 beds by 2030, reinforcing its focus on high-quality Indian healthcare....
6 months ago
Following regulatory scrutiny from FSSAI regarding promotional representations and lean muscle preservation claims, Dr. Reddy's Laboratories and Nestlé Health Science are currently reviewing the branding and marketing strategy for their joint nutritional supplement Celevida GLP+.
Today
A comprehensive scoping review synthesises evidence linking prenatal maternal mental health to long-term offspring neurodevelopment, evaluating neuroendocrine, inflammatory, and epigenetic pathways while highlighting clinical screening and future research priorities.
Today
The Directorate General of Health Services directs Indian states to halt the hazardous reuse and reprocessing of single-use medical devices. Discover regulatory implications under the Drugs and Cosmetics Act, critical infection risks, legal liabilities, and operational changes required across clinical specialties.
Today
A 25-year multi-institutional cohort reveals high recurrence rates in pediatric giant cell tumor of bone, particularly in patients with open physes and bone marrow edema on preoperative MRI. Early surveillance and careful balance between growth plate preservation and tumor clearance are essential.
Today
India is advancing preventive healthcare by integrating genomics, artificial intelligence, and quantum technologies. With the SANGAM programme sequencing one million Indian genomes, clinicians can unlock personalized therapies, detect cardiometabolic risks early, and curb the burden of diabetes and heart disease.
Today
